In vivo anti inflammatory effects of the M20 IL-1 Inhibitor: I. Effects on acute inflammatory parameters

Previous studies have described an IL-1 Inhibitor produced by a myelomonocytic line developed in our laboratory (Eur J Immunol 1986; 16: 1449). This IL-1 Inhibitor was secreted by the M20 line constitutively in addition to IL-1, from which it could be separated. We have recently shown that the M20 IL-1 Inhibitor is distinct from the IL-1ra.In vitro this factor inhibited IL-1 induced proliferative responses as well as PGE₂ secretion by IL-1 induced fibroblasts. We also showed for the first time (Lymphokine Research 1988; 7(3): 268) that an IL-1 inhibitor can reduce IL-1 induced inflammatory effects. This study describes the specific effect of the M20 IL-1 Inhibitor on IL-1 induced parameters of inflammation: fever, leukocytosis and local foot pad swelling or lymph node enlargement. Purified preparations of the IL-1 Inhibitor, when injected together with IL-1, or before the IL-1, reduced fever, leukocytosis, foot pad swelling and lymph node enlargement caused by IL-1. Similar responses were obtained by injection of IL-6 or TNF, but were unaffected by the IL-1 Inhibitor, when injected together.These results indicate that the M20 IL-1 Inhibitor acts specifically on IL-1 induced responsesin vivo. The potential importance of this factor as an anti-inflammatory and immune regulatory factor, is supported by the findings of this study.Abbreviations IL-1 Interleukin 1 - IL-6 Interleukin 6 - IL-1ra Interleukin 1 receptor antagonist - TNF tumor necrosis factor     

ING1 inhibits Twist1 expression to block EMT and is antagonized by the HDAC inhibitor vorinostat

ING1 is a chromatin targeting subunit of the Sin3a histone deacetylase (HDAC) complex that alters chromatin structure to subsequently regulate gene expression. We find that ING1 knockdown increases expression of Twist1, Zeb 1&2, Snai1, Bmi1 and TSHZ1 drivers of EMT, promoting EMT and cell motility. ING1 expression had the opposite effect, promoting epithelial cell morphology and inhibiting basal and TGF-β-induced motility in 3D organoid cultures. ING1 binds the Twist1 promoter and Twist1 was largely responsible for the ability of ING1 to reduce cell migration. Consistent with ING1 inhibiting Twist1 expression in vivo, an inverse relationship between ING1 and Twist1 levels was seen in breast cancer samples from The Cancer Genome Atlas (TCGA). The HDAC inhibitor vorinostat is approved for treatment of multiple myeloma and cutaneous T cell lymphoma and is in clinical trials for solid tumours as adjuvant therapy. One molecular target of vorinostat is INhibitor of Growth 2 (ING2), that together with ING1 serve as targeting subunits of the Sin3a HDAC complex. Treatment with sublethal (LD25-LD50) levels of vorinostat promoted breast cancer cell migration several-fold, which increased further upon ING1 knockout. These observations indicate that correct targeting of the Sin3a HDAC complex, and HDAC activity in general decreases luminal and basal breast cancer cell motility, suggesting that use of HDAC inhibitors as adjuvant therapies in breast cancers that are prone to metastasize may not be optimal and requires further investigation.     

The importance of methylthio-IMP for methylmercaptopurine ribonucleoside (Me-MPR) cytotoxicity in Molt F4 human malignant T-lymphoblasts

The importance of methyl-thioIMP (Me-tIMP) formation for methylmercaptopurine ribonucleoside (Me-MPR) cytotoxicity was studied in Molt F4 cells. Cytotoxicity of Me-MPR is caused by Me-tIMP formation with concomitant inhibition of purine de novo synthesis. Inhibition of purine de novo synthesis resulted in decreased purine nucleotide levels and enhanced 5-phosphoribosyl-1-pyrophosphate (PRPP) levels, with concurrent increased pyrimidine nucleotide levels. The Me-tIMP concentration increased proportionally with the concentration of Me-MPR. High Me-tIMP concentration also caused inhibition of PRPP synthesis. Maximal accumulation of PRPP thus occurred at low Me-MPR concentrations. As little as 0.2 μM Me-MPR resulted already after 2 h in maximal inhibition of formation of adenine and guanine nucleotides, caused by inhibition of purine de novo synthesis by Me-tIMP. Under these circumstances increased intracellular PRPP concentrations could be demonstrated, resulting in increased levels of pyrimidine nucleotides. So, in Molt F4 cells, formation of Me-tIMP form Me-MPR results in cytotoxicity by inhibition of purine de novo synthesis.     

Accumulation of multiacetylated forms of histones by trichostatin A and its developmental consequences in early starfish embryos

Summary External application of 10 rig/ml (R)-trichostatin A (TSA), a potent and specific inhibitor of mammalian histone deacetylase, to the embryo of the starfish Asterina pectinifera inhibited development during the early gastrula stage before formation of mesenchyme cells. The TSA-sensitive period was limited to the mid-blastula stage before hatching. The pulse-chase experiment clearly demonstrated that TSA induced an accumulation of acetylated histone species in blastulae through inhibition of historic deacetylation. Similar blockage of development at the early gastrula stage was observed with n-butyrate, which has been known as a weak inhibitor of historic deacetylase. These results suggest an intimate role for historic acetylation-deacetylation equilibria in starfish development. Correspondence to: S. Ikegami     

Thioredoxin 1 overexpression attenuated diabetes-induced endoplasmic reticulum stress in Müller cells via apoptosis signal-regulating kinase 1

As one of the common and serious chronic complications of diabetes mellitus (DM), the related mechanism of diabetic retinopathy (DR) has not been fully understood. Müller cell reactive gliosis is one of the early pathophysiological features of DR. Therefore, exploring the manner to reduce diabetes-induced Müller cell damage is essential to delay DR. Thioredoxin 1 (Trx1), one of the ubiquitous redox enzymes, plays a vital role in redox homeostasis via protein–protein interactions, including apoptosis signal-regulating kinase 1 (ASK1). Previous studies have shown that upregulation of Trx by some drugs can attenuate endoplasmic reticulum stress (ERS) in DR, but the related mechanism was unclear. In this study, we used DM mouse and high glucose (HG)-cultured human Müller cells as models to clarify the effect of Trx1 on ERS and the underlying mechanism. The data showed that the diabetes-induced Müller cell damage was increased significantly. Moreover, the expression of ERS and reactive gliosis was also upregulated in diabetes in vivo and in vitro. However, it was reversed after Trx1 overexpression. Besides, ERS-related protein expression, reactive gliosis, and apoptosis were decreased after transfection with ASK1 small-interfering RNA in stable Trx1 overexpression Müller cells after HG treatment. Taken together, Trx1 could protect Müller cells from diabetes-induced damage, and the underlying mechanism was related to inhibited ERS via ASK1.     

暗纹东方鲀耐寒相关基因CIRBP、HMGB1和AFP-Ⅳ的分子特征和对低温胁迫的响应

为了探索暗纹东方鲀(Takifugu obscurus)对低温环境的响应机制,克隆了暗纹东方鲀耐寒相关基因CIRBP、HMGB1和AFP-Ⅳ的cDNA序列,并进行了基因的分子特征和功能分析。组织分布检测显示CIRBP和HMGB1在下丘脑、肝脏和肌肉中具有高表达,而AFP-Ⅳ则主要在肝脏中表达。在受到低温胁迫后, 3种基因在肝脏和下丘脑中的表达呈现不同的变化趋势,其中CIRBP基因在肝脏中于48h表达量显著增加,在下丘脑中于12h和48h有上调表达; HMGB1基因在肝脏中呈现逐渐上升的趋势,于48h达到最大值,而在下丘脑中呈现先上升后下降的趋势,处理后2h达到最大, 2—8h下降,于8h下降至最低,随后恢复至初始水平;肝脏中的AFP-Ⅳ在0—24h无显著变化,在48h上升至最大值。进一步通过大肠杆菌原核表达系统研究了AFP-Ⅳ的抗冻功能,发现AFP-Ⅳ融合蛋白在–80℃下具有抗冻活性,并且抗冻活性随着浓度的增加而提高。研究结果表明3种基因都参与了暗纹东方鲀对低温胁迫的应答过程,为深入探索暗纹东方鲀的耐低温机制奠定了基础。     

新型免疫抑制剂brasilicardin A的研究进展

Brasilicardin A (BraA)是从致病性放线菌巴西诺卡菌(Nocardia brasiliensis) IFM 0406中发现的具有显著免疫抑制作用(IC50=0.057μg/mL)的二萜糖苷类化合物。BraA发挥免疫抑制活性的作用机制与现有临床常用的免疫抑制剂不同,BraA通过抑制氨基酸转运体L系统的转运进而影响T-淋巴细胞对氨基酸的摄入而发挥免疫抑制作用。相比目前已知的免疫抑制剂环孢菌素A、子囊霉素和他克莫司等,BraA在小鼠混合淋巴细胞反应中显示低毒、高效的优势。因此,BraA作为新型的免疫抑制剂,极具开发潜力,已成为全球免疫抑制剂发现新领域。但其结构复杂、合成困难,原菌种产率低且具有致病性,BraA及其类似物的获得已成为此类新型免疫抑制剂研究的瓶颈。本文综述了BraA的分子特征、药理活性、作用机制、目前获得的BraA类似物和衍生化方面的研究进展,以期为BraA及其类似物的高效生产提供参考。     

核纤层蛋白B1通过影响端粒酶活性调控肝癌细胞生长

核纤层蛋白B1(nuclear lamina protein B1,LMNB1)高表达于肝癌组织中,通过敲低LMNB1探讨其对肝癌细胞增殖的影响及其机制。利用siRNA在肝癌细胞中敲低LMNB1,Western blotting检测敲低效果,使用端粒重复序列扩增法(telomeric repeat amplification protocol assay,TRAP)检测其端粒酶活性变化。利用实时定量聚合酶链反应(quantitative real-time polymerase chain reaction,qPCR)检测其端粒长度变化。并通过CCK-8、克隆形成、Transwell、划痕实验检测其生长,侵袭和迁移能力变化。利用慢病毒系统构建稳定敲低LMNB1的HepG2细胞,检测其端粒长度及端粒酶活性变化,采用SA-β-gal衰老染色检测细胞衰老情况,通过裸鼠皮下成瘤实验及对肿瘤后续的组化染色,SA-β-gal衰老染色,端粒荧光原位杂交(fluorescence in situ hybridization,FISH)检测其对成瘤性的影响。最后利用生物信息分析的方法寻找LMNB1在临床肝癌组织中的表达情况,及其与临床分期、病人生存期的关系。HepG2和Hep3B中敲低LMNB1后端粒酶活性显著降低,细胞增殖、迁移和侵袭能力显著降低,细胞和裸鼠成瘤实验证明稳定敲低LMNB1后端粒酶活性降低的同时端粒长度缩短,细胞发生衰老,此外细胞成瘤性降低,Ki-67表达降低,生物信息分析结果显示,LMNB1高表达于肝癌组织,且与肿瘤分期和患者生存相关。LMNB1在肝癌细胞中过表达,其有望成为评估肝癌患者临床预后的指标和精准治疗的靶点。